Can signal peptide-CUB-EGF domain-containing protein 1 (SCUBE-1) be used as an indicator of endothelial dysfunction in acromegaly patients?
Göster/ Aç
Erişim
info:eu-repo/semantics/closedAccessTarih
2023Yazar
Tüfekçi, DamlaNuhoğlu, İrfan
Ayan, Sümeyye Şura
Günay, Yasemin Emur
Coşkun, Hülya
Bilginer, Muhammet Cüneyt
Üçüncü, Özge
Koçak, Mustafa
Yaman, Serap Özer
Karahan, Süleyman Caner
Üst veri
Tüm öğe kaydını gösterKünye
Tufekci, D., Nuhoglu, I., Ayan, S. S., Gunay, Y. E., Coskun, H., Bilginer, M. C., Ucuncu, O., Kocak, M., Yaman, S. O., & Karahan, S. C. (2023). Can signal peptide-CUB-EGF domain-containing protein 1 (SCUBE-1) be used as an indicator of endothelial dysfunction in acromegaly patients?. Endocrine, 10.1007/s12020-023-03444-1. Advance online publication. https://doi.org/10.1007/s12020-023-03444-1Özet
PurposeAcromegaly is closely related to increased oxidative stress and endothelial dysfunction (ED). This study aimed to evaluate, for the first time in the literature, signal peptide-CUB-EGF domain-containing protein 1 (SCUBE-1) and endothelial nitric oxide synthase e(NOS) levels in the setting of acromegaly.MethodA total of 56 acromegaly patients and a control group composed of 30 healthy volunteers were included in this study. In the postoperative follow-up, patients were grouped as active or in-remission according to their GH and IGF-1 levels in oral glucose stimulation test (OGST). After detailed physical examination of acromegaly patients and the control subjects, 8-hour fasting blood samples were collected to evaluate biochemical parameters including lipid profile, anterior pituitary hormones, and SCUBE-1 and e(NOS) levels.ResultsInactive and active acromegaly was noted in 78.6% and 21.4% of patients, respectively. The median (min-max) SCUBE-1 levels were significantly higher in the inactive acromegaly and active acromegaly groups than in the control group (1.6(0.4-2.4) and 1.8(1.1-2.5) vs. 0.4(0.2-1.0) ng/mL, respectively, p < 0.001 for each). The median (min-max) e(NOS) levels were significantly higher in the inactive acromegaly and active acromegaly groups than in the control group (132.7 (26.8-602.9) and 137.3 (69.7-488.7) vs. 83.9 (16.4-218.7) pg/mL, p = 0.018 and p = 0.048, respectively). We have also detected positive correlations of e(NOS) with leukocyte (r = 0.307, p = 0.021) and neutrophil counts (r = 0.309, p = 0.021).ConclusionOur study revealed for the first time in literature that SCUBE-1 levels, being a novel marker for ED, were significantly higher in acromegaly patients than in control subjects. When supported with clinical studies, SCUBE-1can be used as an early indicator of endothelial damage in acromegaly patients.